Untrained or home use
In a second aspect, the invention relates to a method for monitoring the progression of an adrenoleukodystrophy in a subject suffering from adrenoleukodystrophy comprising determining in a sample from said subject a value selected from the group consisting of the levels of sphingosine-1-phosphate, the expression levels of sphingosine kinase 2, the expression levels sphingosine-1-phosphate receptor, the expression levels of adiponectin, the levels of at least one marker as defined in Table 1, the levels of at least one marker as defined in Table 2, the levels of at least one marker as defined in Table 3, the levels of at least one marker as defined in Table 4, the expression levels of at least one marker as defined in Table 5, the levels of at least one marker as defined in Table 6, the expression levels of at least one marker as defined in Table 7 and the expression levels of at least one marker as defined in Table 8 wherein increased levels of sphingosine-1-phosphate, increased levels of sphingosine kinase 2, increased levels of sphingosine-1-phosphate receptor, decreased expression levels of adiponectin, increased levels of at least one marker as defined in Table 1, decreased levels of at least one marker as defined in Table 2, increased levels of at least one marker as defined in Table 3, decreased levels of at least one marker as defined in Table 4, increased expression levels of at least one marker as defined in Table 5, increased levels of at least one marker as defined in Table 6, increased expression levels of at least one marker as defined in Table 7, and/or increased expression levels of at least one marker as defined in Table 8 with respect to a value determined in a sample from the same subject at an earlier time point is indicative of a worsening of the adrenoleukodystrophy or wherein decreased levels of sphingosine-1-phosphate, decreased levels of sphingosine kinase 2, decreased levels of sphingosine-1-phosphate receptor, increased expression levels of adiponectin, decreased levels of at least one marker as defined in Table 1, increased levels of at least one marker as defined in Table 2, decreased levels of at least one marker as defined in Table 3, increased levels of at least one marker as defined in Table 4, decreased expression levels of at least one marker as defined in Table 5, decreased levels of at least one marker as defined in Table 6, decreased expression levels of at least one marker as defined in Table 7, and/or decreased expression levels of at least one marker as defined in Table 8 with respect to a value determined in a sample from the same subject at an earlier time point t is indicative of an amelioration of the adrenoleukodystrophy
Davis KE, Carstens EJ, Irani BG, et al
With an international customer base and a growing community of fans, were here to help you feel more confident, comfortable, and preparedon your terms
(b) Limited ability to synthesise the active nucleotide intermediate
In this context, the potential of ENZ-SBA-15@SNCD@FA as a delivery carrier was evaluated
